Pfizer on Feb. 11 said it is postponing its rolling submission to the FDA as it waits for data on a three-dose COVID-19 vaccine regimen for children under 5. The extension means vaccines for young children will not be available later this month as federal health officials had anticipated.
Read the full post on Becker's Hospital Review - Healthcare News
